NVIDIA Launches $1 Billion AI Drug Discovery Lab with Lilly, Expands BioNeMo Platform
Summary
NVIDIA launches a $1 billion AI drug discovery lab with pharmaceutical giant Lilly and expands its BioNeMo platform, partnering with major life sciences companies to automate scientific discovery through AI models that predict molecular structures and connect digital agents to robotic laboratory systems.
Key Points
- NVIDIA expands its BioNeMo platform for AI-driven drug discovery, launching a $1 billion co-innovation lab with Lilly and partnering with Thermo Fisher to build autonomous laboratory infrastructure
- Major life sciences companies including Basecamp Research, Chai Discovery, and Boltz are adopting BioNeMo to accelerate biological foundation model development and molecular design
- The platform integrates new AI models for RNA structure prediction and drug synthesis, while connecting digital agents to physical robotics systems to automate the entire scientific discovery process